PRL and urinary bladder cancer: Key enriched pathways included proteoglycans in cancer, estrogen signaling, EGFR tyrosine kinase inhibitor resistance, prolactin signaling, ErbB signaling, HIF-1 signaling, PD-L1 expression and PD-1 checkpoint, FoxO signaling, PI3K-Akt signaling, pathways in cancer, prostate cancer, bladder cancer, pancreatic cancer, gastric cancer, and breast cancer.